WESTFORD, Mass., Nov. 6, 2013 /PRNewswire/ -- Cynosure,
Inc. (NASDAQ: CYNO), a leader in laser- and light-based
aesthetic treatments for non-invasive and minimally invasive
applications, today announced that Australia's Therapeutic Goods Administration
has granted marketing clearance for the PicoSure™ Picosecond Laser,
the world's first picosecond laser for the removal of tattoos and
benign pigmented lesions. PicoSure was introduced in the United States earlier this year after
receiving clearance from the U.S. Food and Drug Administration. The
product also is being marketed in the European Union and
Canada.
"PicoSure continues to be enthusiastically received by
physicians and consumers in North
America and Europe, and we
are excited about the opportunity to market the product to our
customers and their patients in Australia, which is a new direct sales
territory for the Company," said Cynosure President and CEO
Michael Davin.
The Company also received approval from the China Food and Drug
Administration to market Smartlipo MPX™ LaserBodySculpting™
Workstation, the industry's leading laser-assisted lipolysis system
designed to disrupt fat cells and tighten tissue through tissue
coagulation. In addition, the PinPointe™ FootLaser™, which Cynosure
distributes through an exclusive worldwide agreement with NuvoLase
Inc., has been cleared by the Korea Food & Drug Administration
for the treatment of Onychomycosis, commonly known as nail
fungus.
"Further expanding our international product reach is an
important part of our long-term growth strategy," Davin said.
"International markets generate nearly half of our total laser
revenue. Our goal is to continue to enhance our presence in
high-growth regions by capitalizing on our outstanding brand
reputation, broad distribution capabilities and strong customer
relationships. With our innovative laser treatments rapidly gaining
in popularity and accessibility around the world, Cynosure is
playing an integral role in driving the growth of the global
aesthetic market."
About Cynosure, Inc.
Cynosure develops and markets
aesthetic treatment systems that enable plastic surgeons,
dermatologists and other medical practitioners to perform
non-invasive and minimally invasive procedures to remove hair,
treat vascular and benign pigmented lesions, remove multi-colored
tattoos, revitalize the skin, liquefy and remove unwanted fat
through laser lipolysis, reduce cellulite, clear nails infected by
toe fungus and ablate sweat glands. Cynosure's product
portfolio is composed of a broad range of energy sources including
Alexandrite, diode, Nd: YAG, picosecond, pulse dye, and Q-switched
lasers and intense pulsed light. Cynosure sells its products
globally under the Cynosure, Palomar and ConBio brand names through
a direct sales force in the United
States, Canada,
Mexico, France, Germany, Spain, the United
Kingdom, Australia,
China, Japan and Korea, and through international
distributors in approximately 100 other countries. For
corporate or product information, visit Cynosure's website at
www.cynosure.com.
Forward-Looking Statements
Any statements in this
press release about future expectations, plans and prospects for
Cynosure, Inc., as well as other statements containing the words
"believes," "anticipates," "plans," "expects," "will" and similar
expressions, constitute forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by such
forward-looking statements as a result of various important
factors, including market acceptance of PicoSure in Australia, market acceptance of Smartlipo MPX
in China, market acceptance of the
PinPointe FootLaser in Korea, levels of demand for procedures
performed with Cynosure products and for Cynosure products
themselves, competition in the aesthetic laser industry, general
business and economic conditions and other factors discussed in
Cynosure's most recent Annual Report on Form 10-K and subsequently
filed quarterly reports on Form 10-Q, which are filed with the
Securities and Exchange Commission. In addition, the
forward-looking statements included in this press release represent
Cynosure's views as of the date of this press release. Cynosure
anticipates that subsequent events and developments will cause its
views to change. However, although Cynosure may elect to update
these forward-looking statements at some point in the future, it
specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing Cynosure's views as of any date subsequent to the date
of this press
release.
Contact:
Scott Solomon
Vice President
Sharon Merrill Associates, Inc.
617.542.5300
cyno@investorrelations.com
SOURCE Cynosure